Correlation between insulin resistance and serum ghrelin in non-diabetic ankylosing spondylitis patients undergoing anti-TNF-α therapy

Clinical and Experimental Rheumatology

Volumn 31, Issue 6, 2013, Pages 913-918

  Genre, F ^a   Lopez Mejias R ^a   Miranda Filloy, J A ^b   Carnero Lopez B ^c   Gomez Acebo I ^d   Blanco, R ^a   Ochoa, R ^a   Rueda, J ^a   Gonzalez Juanatey C ^b   Llorca, J ^d   Gonzalez Gay M A ^a  

^a Epidemiology Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases   (Spain)

^b HOSPITAL XERAL CALDE   (Spain)

^c HOSPITAL EL BIERZO   (Spain)

^d UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Ankylosing spondylitis; Anti TNF antibody infliximab; Ghrelin; Inflammation; Insulin resistance

Indexed keywords

ADIPOCYTOKINE; C REACTIVE PROTEIN; GHRELIN; INFLIXIMAB; RESISTIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR INHIBITOR;

ADOLESCENT; ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ARTICLE; CORRELATIONAL STUDY; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; METABOLIC DISORDER; NONDIABETIC ANKYLOSING SPONDYLITIS; OBESITY; PRIORITY JOURNAL; REFRACTORY PERIOD;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; GHRELIN; HUMANS; INFUSIONS, INTRAVENOUS; INSULIN RESISTANCE; MALE; MIDDLE AGED; RESISTIN; SPONDYLITIS, ANKYLOSING; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84892455294     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. AZEVEDO VF, PECOITS-FILHO R. Atherosclerosis and endothelial dysfunction in patients with ankylosing spondylitis. Rheumatol Int 2010; 30: 1411-6.
2. CAPKIN E, KIRIS A, KARKUCAK M, et al. Joint Investigation of effects of different treatment modalities on structural and functional vessel wall properties in patients with ankylosing spondylitis. Bone Spine 2011; 78: 378-82.
3. GONZALEZ-JUANATEY C, VAZQUEZ-RODRIGUEZ TR, MIRANDA-FILLOY JA, et al. The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore) 2009; 88: 358-65.
4. PETERS MJ, van EIJK IC, SMULDERS YM, et al. Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 2010; 37: 161-6.
5. BODNÁR N, KEREKES G, SERES I, et al. Assessment of subclinical vascular disease associated with ankylosing spondylitis. J Rheumatol 2011; 38: 723-9.
6. PETERS MJ, VISMAN I, NIELEN MM, et al. Ankylosing spondylitis: a risk factor for myocardial infarction? Ann Rheum Dis 2010; 69: 579-81.
7. BAATAR D, PATEL K, TAUB DD. The effects of ghrelin on inflammation and the immune system. Mol Cell Endocrinol 2011; 340: 44-58.
8. DIXIT VD, SCHAFFER EM, PYLE RS, et al. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 2004; 114: 57-66.
9. MIRANDA-FILLOY JA, LLORCA J, CARNERO-LÓPEZ B, GONZÁLEZ-JUANATEY C, BLANCO R, GONZÁLEZ-GAY MA. TNF-α antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients. Clin Exp Rheumatol 2012; 30: 850-5.
10. MIRANDA-FILLOY JA, LÓPEZ-MEJIAS R, GENRE F, et al. Adiponectin and resistin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy. Clin Exp Rheumatol 2013; 31: 365-71.
11. MIRANDA-FILLOY JA, LÓPEZ-MEJIAS R, GENRE F, et al. Leptin and visfatin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy. Clin Exp Rheum 2013; 31: 538-45.
12. GENRE F, MIRANDA-FILLOY JA, LÓPEZ-MEJIAS R, et al. Apelin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy. Clin Exp Rheumatol 2013; 31: 532-7.
13. D'ANGELO S, PALAZZI C, CANTINI F, et al. Etanercept in spondyloarthopathies. Part II: safety and pharmacoeconomic issues. Clin Exp Rheumatol 2011; 29: 865-70.
14. PALAZZI C, D'ANGELO S, CANTINI F, et al. Etanercept in spondyloarthropathies. Part I: current evidence of efficacy. Clin Exp Rheumatol 2011; 29: 858-64.
15. HELDMANN F, BRANDT J, van der HORST-BRUINSMA IE, et al. The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 2011; 29: 672-80.
16. van der LINDEN S, VALKENBURG HA, CATS A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-8.
17. VIS M, NURMOHAMED MT, WOLBINK G, et al. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 252-5.
18. GONZALEZ-GAY MA, GARCIA-UNZUETA MT, GONZALEZ-JUANATEY C, et al. Anti- TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 311-6.
19. GONZALEZ-GAY MA, GARCIA-UNZUETA MT, DE MATIAS JM, et al. Influence of anti- TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 373-9.
20. BRAUN J, van den BERG R, BARALIAKOS X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 70: 896-904.
21. GARRETT S, JENKINSON T, KENNEDY LG, WHITELOCK H, GAISFORD P, CALIN A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286-91.
22. TSCHÖP M, WEYER C, TATARANNI PA, DEVANARAYAN V, RAVUSSIN E, HEIMAN ML. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001; 50: 707-9.
23. FLANAGAN DE, EVANS ML, MONSOD TP, et al. The influence of insulin on circulating ghrelin. Am J Physiol Endocrinol Metab 2003; 284: E313-6.
24. IKEZAKI A, HOSODA H, ITO K, et al. Fasting plasma ghrelin levels are negatively correlated with insulin resistance and PAI-1, but not with leptin, in obese children and adolescents. Diabetes 2002; 51: 3408-11.
25. PÖYKKÖ SM, KELLOKOSKI E, HÖRKKÖ S, KAUMA H, KESÄNIEMI YA, UKKOLA O. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 2003; 52: 2546-53.
26. LAZAR MA. Resistin- and Obesity-associated metabolic diseases. Horm Metab Res 2007 Oct; 39: 710-6.
27. SCHWARTZ DR, LAZAR MA. Human resistin: found in translation from mouse to man. Trends Endocrinol Metab 2011; 22: 259-65.
28. PURNELL JQ, WEIGLE DS, BREEN P, CUMMINGS DE. Ghrelin levels correlate with insulin levels, insulin resistance, and high-density lipoprotein cholesterol, but not with gender, menopausal status, or cortisol levels in humans. J Clin Endocrinol Metab 2003; 88: 5747-52.
29. GONZALEZ-GAY MA, GARCIA-UNZUETA MT, BERJA A, et al. Anti-tumour necrosis factor alpha therapy modulates ghrelin in patients with severe rheumatoid arthritis. Ann Rheum Dis 2008; 67: 1644-6.
30. TOUSSIROT E, STREIT G, NGUYEN NU, et al. Adipose tissue, serum adipokines, and ghrelin in patients with ankylosing spondylitis. Metabolism 2007; 56: 1383-9.
31. OTERO M, NOGUEIRAS R, LAGO F, DIEGUEZ C, GOMEZ-REINO JJ, GUALILLO O. Chronic inflammation modulates ghrelin levels in humans and rats. Rheumatology (Oxford) 2004; 43: 306-10.